PLGA-PEG investigated for drug-delivery treatment of Leishmaniasis
PolySciTech division of
Akina, Inc. (www.polyscitech.com)
provides a wide array of PLGA-PEG block copolymers. Recently, these kinds of
polymers were used to develop a nanoparticle system to deliver miltefosine to
Leishmania donovani as a treatment of Leishmaniasis. Read more: Kumar,
Rishikesh, Ganesh Chandra Sahoo, Krishna Pandey, V. N. R. Das, Roshan K. Topno,
Md Yousuf Ansari, Sindhuprava Rana, and Pradeep Das. "Development of
PLGA–PEG encapsulated miltefosine based drug delivery system against visceral
leishmaniasis." Materials Science and Engineering: C 59 (2016): 748-753. http://www.sciencedirect.com/science/article/pii/S0928493115305154
“Abstract: Targeted
drug delivery systems are ideal technology to increase the maximum mechanism of
action with smaller dose, we have developed miltefosine encapsulated PLGA–PEG
nanoparticles (PPEM) to target macrophage of infected tissues against
Leishmania donovani. The structural characterization of PLGA–PEG by
transmission electron microscopy (TEM) has shown a size range of 10 to 15 nm.
Synthesis and drug encapsulation confirmed by dynamic light scattering (DLS)
and Fourier transform infrared spectroscopy (FTIR) and confirmed NP
encapsulation. The dose of nano encapsulated miltefosine decreased by fifty
percent as compared to that of a conventional miltefosine and Amphoterecin B.
The inhibition of amastigotes in the splenic tissue with nano encapsulated
miltefosine (23.21 ± 23) was significantly more than the conventional
miltefosine (89.22 ± 52.7) and Amphoterecin B (94.12 ± 55.1). This study signifies
that there is an increased contact surface area of the nano encapsulated drug
and significant reduction in size, improved the efficacy in both in vitro and
in vivo study than that of the conventional miltefosine, Amphoterecin B. Graphical
abstract: The analyses of detailed structure characterized by TEM and DLS
confirmed the nano-size of the particle 10–20 nm and FTIR confirmed for
antileishmanial drug encapsulation in to PLGA–PEG. The dose of miltefosine is
decreased by fifty percent as the IC50 value is decreased from 0.2 to 0.1 μg.
Further inhibitions of amastigotes in the splenic tissue with these
nanoparticles are significantly more than the conventional miltefosine and
PLGA–PEG encapsulated Amphoterecin B (23.21 ± 23/89.09 ± 52.7/92.12 ± 55.1). Keywords:
Miltefosine; Transmission electron microscope; Nanoscale; Amastigotes;
Amphoterecin B”
No comments:
Post a Comment